Rallybio Corporation (NASDAQ: RLYB) related to its merger with Candid Therapeutics, Inc. Upon completion of the proposed transaction, Rallybio shareholders are expected to own approximately 3.65% of the combined company.
Rallybio Corporation (NASDAQ: RLYB) related to its merger with Candid Therapeutics, Inc. Upon completion of the proposed transaction, Rallybio shareholders are expected to own approximately 3.65% of the combined company.